Merck hands Swedish biotech €10M cash to develop anti-inflammatory drugs
Merck is betting on Aqilion’s work on a small molecule inhibitor for autoimmune and inflammatory diseases, including neurological diseases.
Merck is paying €10 million upfront cash to the Swedish-based biotech in a licensing deal and research collaboration to develop small molecule inhibitors of the growth factor-β-activated kinase 1 (TAK1) with the potential for another €950 million in development and commercialization milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.